Spectral Diagnostics Earnings Date & Estimates

Spectral Diagnostics (OTCMKTS:EDTXF), now known as Spectral Medical Inc., is a Canadian medical-device and biotechnology company focused on the diagnosis and treatment of sepsis and other conditions associated with systemic inflammation. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and contribute to severe immune responses.

Spectral’s principal diagnostic product is the Endotoxin Activity Assay, or EAA, a blood test designed to measure a patient’s endotoxin activity and help clinicians assess the risk of developing severe sepsis. The company has also been involved in the development and commercialization of blood-purification therapies, including polymyxin B hemoperfusion technology intended to remove endotoxins from the bloodstream.

Headquartered in Toronto, Ontario, Spectral has historically worked with medical-device and pharmaceutical partners to support the regulatory approval, development and distribution of its products in North America and international markets. Its business remains focused on advancing diagnostic and therapeutic technologies for critically ill patients, particularly those with septic shock.